tetano
Editor, Senior Moderator
Vaccines (Basel)
. 2021 Jan 7;9(1):E26.
doi: 10.3390/vaccines9010026.
The Next Generation of Influenza Vaccines: Towards a Universal Solution
Christopher L D McMillan[SUP] 1 [/SUP], Paul R Young[SUP] 1 2 3 [/SUP], Daniel Watterson[SUP] 1 3 [/SUP], Keith J Chappell[SUP] 1 2 3 [/SUP]
Affiliations
Abstract
Influenza viruses remain a constant burden in humans, causing millions of infections and hundreds of thousands of deaths each year. Current influenza virus vaccine modalities primarily induce antibodies directed towards the highly variable head domain of the hemagglutinin protein on the virus surface. Such antibodies are often strain-specific, meaning limited cross-protection against divergent influenza viruses is induced, resulting in poor vaccine efficacy. To attempt to counteract this, yearly influenza vaccination with updated formulations containing antigens from more recently circulating viruses is required. This is an expensive and time-consuming exercise, and the constant arms race between host immunity and virus evolution presents an ongoing challenge for effective vaccine development. Furthermore, there exists the constant pandemic threat of highly pathogenic avian influenza viruses with high fatality rates (~30-50%) or the emergence of new, pathogenic reassortants. Current vaccines would likely offer little to no protection from such viruses in the event of an epidemic or pandemic. This highlights the urgent need for improved influenza virus vaccines capable of providing long-lasting, robust protection from both seasonal influenza virus infections as well as potential pandemic threats. In this narrative review, we examine the next generation of influenza virus vaccines for human use and the steps being taken to achieve universal protection.
Keywords: hemagglutinin; influenza; pandemic; universal influenza vaccine; vaccine.
. 2021 Jan 7;9(1):E26.
doi: 10.3390/vaccines9010026.
The Next Generation of Influenza Vaccines: Towards a Universal Solution
Christopher L D McMillan[SUP] 1 [/SUP], Paul R Young[SUP] 1 2 3 [/SUP], Daniel Watterson[SUP] 1 3 [/SUP], Keith J Chappell[SUP] 1 2 3 [/SUP]
Affiliations
- PMID: 33430278
- DOI: 10.3390/vaccines9010026
Abstract
Influenza viruses remain a constant burden in humans, causing millions of infections and hundreds of thousands of deaths each year. Current influenza virus vaccine modalities primarily induce antibodies directed towards the highly variable head domain of the hemagglutinin protein on the virus surface. Such antibodies are often strain-specific, meaning limited cross-protection against divergent influenza viruses is induced, resulting in poor vaccine efficacy. To attempt to counteract this, yearly influenza vaccination with updated formulations containing antigens from more recently circulating viruses is required. This is an expensive and time-consuming exercise, and the constant arms race between host immunity and virus evolution presents an ongoing challenge for effective vaccine development. Furthermore, there exists the constant pandemic threat of highly pathogenic avian influenza viruses with high fatality rates (~30-50%) or the emergence of new, pathogenic reassortants. Current vaccines would likely offer little to no protection from such viruses in the event of an epidemic or pandemic. This highlights the urgent need for improved influenza virus vaccines capable of providing long-lasting, robust protection from both seasonal influenza virus infections as well as potential pandemic threats. In this narrative review, we examine the next generation of influenza virus vaccines for human use and the steps being taken to achieve universal protection.
Keywords: hemagglutinin; influenza; pandemic; universal influenza vaccine; vaccine.